STAT+: Leaked study results show a CAR-T from J&J providing big benefit for patients with multiple myeloma
The CAR-T cancer therapy called Carvykti reduced the risk of relapse by 74% compared to standard treatment in patients with multiple myeloma, according to results from a Phase 3 study…
The CAR-T cancer therapy called Carvykti, made by Johnson & Johnson and Legend Biotech, reduced the risk of relapse by 74% compared to standard treatment in patients with multiple myeloma, according to results from a Phase 3 study that leaked online Tuesday night.
The magnitude of the patient benefit reported from the study called CARTITUDE-4 is much better than expected, and if cleared by regulators, will likely persuade doctors to use the personalized cell therapy earlier in the course of treatment of multiple myeloma.
What's Your Reaction?
